A practical reference on Tesamorelin: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-05-22 and is reviewed periodically as new material appears.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | 44 residues; N-terminal trans-3-hexenoyl group |
| First approval year | 2010 | United States; HIV-associated abdominal fat accumulation |
| Administration route | Subcutaneous injection | Abdominal site; clinician-administered or self-injected |
| Common synonyms | TH9507; tesamorelin acetate | Development code and acetate salt form |
| Originator | Canadian biotechnology firm | Original developer and regulatory sponsor |
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
=== Scope of the national home "in Palestine" === The statement that such a homeland would be found "in Palestine" rather than "of Palestine" was also deliberate. The proposed draft of the declaration contained in Rothschild's 12 July letter to Balfour referred to the principle "that Palestine should be reconstituted as the National Home of the Jewish people." In the final text, following Lord Milner's amendment, the word "reconstituted" was removed and the word "that" was replaced with "in". This text thereby avoided committing the entirety of Palestine as the National Home of the Jewish people, resulting in controversy in future years over the intended scope, especially the Revisionist Zionism sector, which claimed entirety of Mandatory Palestine and Emirate of Transjordan as Jewish Homeland This was clarified by the 1922 Churchill White Paper, which wrote that "the terms of the declaration referred to do not contemplate that Palestine as a whole should be converted into a Jewish National Home, but that such a Home should be founded 'in Palestine.'" The declaration did not include any geographical boundaries for Palestine. Following the end of the war, three documents – the declaration, the McMahon–Hussein correspondence and the Sykes–Picot Agreement – became the basis for the negotiations to set the boundaries of Palestine.
== Function == GSTK1 has been suggested to promote adiponectin multimerization in the endoplasmic reticulum (ER), but this has been contradicted by later studies. GSTK1 can prevent ER stress and ER stress-induced adiponectin down-regulation, implying that GSTK1 assists the ER’s functions. GSTK1 is located in the ER and also in the mitochondria of hepatocytes. This indicates a potential role for GSTK1 in the interaction between the two organelles; though this is poorly understood. The discovery of GSTK1 in the peroxisome has led to studies based on its function. It has been suggested that, similar to GSTA, GSTK1 may play a role in the buffering of acyl-CoA and xenobiotic-CoA and be involved in their binding activities. GSTK1 may also be responsible for the detoxification of lipid peroxides created in the peroxisome based on the peroxidase activity towards three substrates: tert-butyl hydroperoxide, cumene hydroperoxide, and 15-S-hydroperoxy-5,8,11,13-eicosatetraenoic acid.
The actions undertaken in Canada to support incoming aircraft and their occupants were collectively titled Operation Yellow Ribbon. That evening, the Central Intelligence Agency informed President George W. Bush that its Counterterrorism Center had identified the attacks as having been the work of al-Qaeda under Osama bin Laden. The United States responded by invading Afghanistan and launching its Global War on Terror, with the stated goal of eliminating hostile groups it deemed terrorist organizations and the governments the United States identified as supporting them. NATO's invocation of Article 5 of the North Atlantic Treaty—its only usage to date—called upon allies to fight al-Qaeda as well. As U.S. and allied invasion forces swept through Afghanistan, bin Laden eluded them. He denied any involvement until 2004, when excerpts of a taped statement in which he accepted responsibility for the attacks were released. Al-Qaeda's cited motivations included U.S. support of Israel, the presence of U.S. military bases in Saudi Arabia, and sanctions against Iraq. The nearly decade-long manhunt for bin Laden concluded in May 2011, when he was killed during a U.S. military raid in Abbottabad, Pakistan. The war in Afghanistan continued for another decade. The attacks killed 2,977 people, injured thousands more, and gave rise to long-term health consequences while causing at least US$10 billion in infrastructure and property damage.
. From here, one might attempt to solve the Schrödinger equation for this Hamiltonian directly in its current form. However, it proves far more analytically bountiful to take advantage of the fact that this system is actually isomorphic to three uncoupled harmonic oscillators. One need only define the ladder operators
Sources: en.wikipedia.org
However, the eras of the two empires also witnessed a steady erosion of women's rights, and, by the end, the institutionalisation of untouchability. In South India, the Sangam literature of the Tamil language reveals that, between 200 BCE and 200 CE, the southern peninsula was ruled by the Cheras and the Cholas, along the western and eastern plains, respectively, of the Kaveri river valley, and the Pandyas farther south along the Vaigai river valley. By the sixth century, the Pallavas had grown into a regional power. Simultaneously, Buddhism and Jainism, which had favoured a conservative transactionalism, were replaced by kingly devotion to the gods of particular places, which became a characteristic of the Bhakti movement. The Pallavas, in particular, traded extensively with the Roman Empire and with West and Southeast Asia.
== Comparison with LASIK == Some theoretical advantages are that the technique is minimally invasive compared with LASIK and no collateral damage occurs to surrounding tissue due to the high speed of the femtosecond laser. There are limited studies on corneal wound healing and inflammatory response after this treatment has been carried out. There is a suggestion that the expression of fibronectin which is associated with wound healing is less in this method compared with femtosecond-LASIK. In some cases post operative tear secretion and dry eye syndrome have been observed along with similar post operative complications seen in LASIK surgery. Like PRK and LASEK, SMILE prevents the flap-related risks for example in contacts sports.
Historically, Japanese consumption of animal products primarily focused on seafood. Influenced by Buddhist precepts against killing (sesshō) and the Shinto reverence for rice cultivation, meat from mammals and birds was often considered impure (kegare) and rarely eaten. Although domesticated chickens arrived in Japan during the Yayoi period, imperial edicts, such as those by Emperor Tenmu and Emperor Shōmu, forbade the killing and eating of certain animals, including chickens, and eggs were likely avoided as well. During the Sengoku period and Edo period, contact with Europeans, particularly in Western Japan, introduced meat-eating habits and the consumption of eggs. Namban confectionery using eggs, such as castella and bōro, also arrived. An early dish resembling TKG, called Tamago meshi (玉子飯, egg rice), appears in the 1805 cookbook Shirōto Hōchō (素人包丁, Amateur Cooking). It involved pouring beaten egg over cooked rice and steaming it. In 1838, records from the Nabeshima clan (Onji Nikki) mention "Odonburi Namatamago" (御丼 生玉子, bowl of rice [with] raw egg) being served to guests. The first person known to have eaten TKG in its modern, raw form was Kishida Ginkō (1833–1905), a pioneering journalist, around 1877. He reportedly recommended the dish to others. According to a 1927 magazine article describing Ginkō's habits, he seasoned it with salt and chili pepper (bansho). Eggs were a luxury during the food shortages after World War II, but became widely affordable from the 1950s onwards. TKG then gained popularity for its taste and nutritional value.
== Epigenetic effects == The honey bee queens and workers represent one of the most striking examples of environmentally controlled phenotypic polymorphism. Even if two larvae had identical DNA, one raised to be a worker, the other a queen, the two adults would be strongly differentiated across a wide range of characteristics including anatomical and physiological differences, longevity, and reproductive capacity. Queens constitute the female sexual caste and have large active ovaries, whereas female workers have only rudimentary, inactive ovaries and are functionally sterile. The queen–worker developmental divide is controlled epigenetically by differential feeding with royal jelly; this appears to be due specifically to the protein royalactin. A female larva destined to become a queen is fed large quantities of royal jelly; this triggers a cascade of molecular events resulting in development of a queen. It has been shown that this phenomenon is mediated by an epigenetic modification of DNA known as CpG methylation. Silencing the expression of an enzyme that methylates DNA in newly hatched larvae led to a royal jelly-like effect on the larval developmental trajectory; the majority of individuals with reduced DNA methylation levels emerged as queens with fully developed ovaries. This finding suggests that DNA methylation in honey bees allows the expression of epigenetic information to be differentially altered by nutritional input.
There is no known specific preventive measure for type 1 diabetes. However, islet autoimmunity and multiple antibodies can be a strong predictor of the onset of type 1 diabetes. Type 2 diabetes—which accounts for 85–90% of all cases worldwide—can often be prevented or delayed by maintaining a normal body weight, engaging in physical activity, and eating a healthy diet. Higher levels of physical activity (more than 90 minutes per day) reduce the risk of diabetes by 28%. Dietary changes known to be effective in helping to prevent diabetes include maintaining a diet rich in whole grains and fiber, and choosing good fats, such as the polyunsaturated fats found in nuts, vegetable oils, and fish. Limiting sugary beverages and eating less red meat and other sources of saturated fat can also help prevent diabetes. Tobacco smoking is also associated with an increased risk of diabetes and its complications, so smoking cessation can be an important preventive measure as well. The relationship between type 2 diabetes and the main modifiable risk factors (excess weight, unhealthy diet, physical inactivity and tobacco use) is similar in all regions of the world. There is growing evidence that the underlying determinants of diabetes are a reflection of the major forces driving social, economic and cultural change: globalization, urbanization, population aging, and the general health policy environment.
Sources: en.wikipedia.org
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.
The clinical program was designed around HIV-associated lipodystrophy, a condition in which fat accumulates abnormally around the internal organs. Trials enrolled that specific population, so the evidence base covers it rather than the general population. Regulators approved the drug for the studied indication only, and promotion outside it is not permitted.
Growth hormone therapy supplies the finished hormone directly, while this peptide acts upstream and asks the pituitary to secrete its own. That difference means the response depends on a functioning pituitary and on the body's normal feedback loops. It also means the circulating hormone profile is pulsatile rather than a flat, injected level.
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.